losartan has been researched along with pentoxifylline in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Georgescu, EF; Georgescu, M | 1 |
| Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD | 1 |
| Larczyński, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Zietkiewicz, M | 1 |
| Ahn, JS; Cho, JH; Choi, JY; Hyun, SH; Kim, CD; Kim, YL; Oh, EJ; Oh, SH; Park, SH; Ryu, HM; Yoon, SH | 1 |
| Afarideh, M; Dehghani Firouzabadi, F; Esteghamati, A; Esteghamati, S; Ganji, M; Ghajar, A; Heidari, B; Najafi, MT; Nakhjavani, M; Noshad, S; Rabizadeh, S; Saadat, M | 1 |
| Eslahi, A; Karbalay-Doust, S; Khoshnood, O; Noorafshan, A; Shirazi, M | 1 |
| Benard, F; Bennewith, KL; Cederberg, RA; Colpo, N; Firmino, NS; Franks, SE; Lee, CM; Lin, KS; Pan, J; Wadsworth, BJ | 1 |
1 review(s) available for losartan and pentoxifylline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for losartan and pentoxifylline
| Article | Year |
|---|---|
Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
Topics: Adult; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cholagogues and Choleretics; Fatty Liver; Female; Hematologic Agents; Hepatitis; Heptanoic Acids; Humans; Losartan; Male; Middle Aged; Pentoxifylline; Pyrroles; Treatment Outcome; Ursodeoxycholic Acid | 2007 |
Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Chemokine CCL2; Chronic Disease; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney Diseases; Losartan; Male; Middle Aged; Pentoxifylline; Phosphodiesterase Inhibitors; Proteinuria; Tumor Necrosis Factor-alpha | 2008 |
Beneficial Effects of Pentoxifylline Plus Losartan Dual Therapy in Type 2 Diabetes with Nephropathy.
Topics: Atrial Natriuretic Factor; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Humans; Losartan; Male; Middle Aged; Pentoxifylline; Protein Precursors; Serum Albumin, Human; Treatment Outcome | 2018 |
8 other study(ies) available for losartan and pentoxifylline
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
[Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hepatitis C; Humans; Hypertension; Kidney Diseases; Lisinopril; Losartan; Male; Middle Aged; Pentoxifylline; Proteinuria | 2008 |
Effects of losartan and pentoxifylline on renal dimethylarginine dimethylaminohydrolase-1 expression in proteinuric nephropathy.
Topics: Acetylglucosaminidase; Albuminuria; Amidohydrolases; Angiotensin II Type 1 Receptor Blockers; Animals; Arginine; Cell Line; Free Radical Scavengers; Kidney Tubules, Proximal; Losartan; Oxidative Stress; Pentoxifylline; Rats; Reactive Oxygen Species | 2013 |
Comparison of the effects of pentoxifylline, simvastatin, tamoxifen, and losartan on cavernous bodies after penile fracture in rats: a stereological study.
Topics: Animals; Fibrosis; Losartan; Male; Penile Diseases; Pentoxifylline; Rats; Simvastatin; Tamoxifen | 2020 |
Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cancer-Associated Fibroblasts; Cell Line, Tumor; Collagen Type I; Fluorescent Dyes; Humans; Losartan; Mice; Neoplasms; Pentoxifylline; Positron-Emission Tomography; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy; Telmisartan; Tumor Hypoxia; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |